Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2005-10-18

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 491

Registration Number: NCT00240435

Locations: 🇨🇦
St. Boniface General Hospital, Winnipeg, Manitoba, Canada
🇺🇸
University of California - Los Angeles, Los Angeles, California, United States
🇨🇦
Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada

and more 8 locations

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2005-10-17

Last Posted Date: 2023-12-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 131

Registration Number: NCT00239447

Locations: 🇺🇸
National Jewish Medical and Research Center, Denver, Colorado, United States
🇺🇸
Division of Pulmonary and Critical Care Medicine, Little Rock, Arkansas, United States
🇺🇸
LSU MC-Sheveport, Shreveport, Louisiana, United States

and more 6 locations

Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD)

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2005-10-17

Last Posted Date: 2013-11-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 107

Registration Number: NCT00239499

Locations: 🇿🇦
Boehringer Ingelheim Investigational Site, Welkom, South Africa
🇿🇦
Tijger Trial Centre, Bellville, South Africa
🇿🇦
Durban Lung Centre, Durban, South Africa

and more 5 locations

Efficacy and Safety (Including 24-hour Holter Monitoring) of Tiotropium Inhalation Capsules in Patients With COPD

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2005-10-17

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 196

Registration Number: NCT00239460

Locations: 🇺🇸
Attn: William C. Bailey, M.D., Birmingham, Alabama, United States
🇺🇸
Boehringer Ingelheim Investigational Site, Houston, Texas, United States
🇺🇸
The Oregon Clinic, Portland, Oregon, United States

and more 5 locations

12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2005-10-17

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 429

Registration Number: NCT00239473

Locations: 🇨🇭
Ospedale San Giovanni, Bellinzona, Switzerland
🇨🇭
Kantonsspital St. Gallen, St. Gallen, Switzerland
🇮🇹
Ospedale Silvestrini, San Sisto (pg), Italy

and more 25 locations

A Study to Compare Meloxicam IM Once Daily Versus Meloxicam Orally Once Daily in Patients With Rheumatoid Arthritis

Phase 3

Completed

Conditions: Arthritis, Rheumatoid

First Posted Date: 2005-10-17

Last Posted Date: 2018-08-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 150

Registration Number: NCT00239382

Locations: 🇨🇳
Shanghai Zhongshan Hospital, Shanghai, China
🇨🇳
Shanghai Guanghai Hospital, Shanghai, China
🇨🇳
People's Hospital, Beijing University, Beijing, China

and more 5 locations

A Comparison of 18g of Tiotropium Inhalation Capsules Once Daily and Atrovent Metered Dose Inhaler (2 Puffs of 20g, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2005-10-17

Last Posted Date: 2012-05-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 200

Registration Number: NCT00239434

Locations: 🇨🇳
Zhongshan Hospital of Fudan University, Shanghai, China
🇨🇳
People Hospital of Beijing University, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Beijing, China

and more 3 locations

A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2005-10-17

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 605

Registration Number: NCT00239421

Locations: 🇦🇹
Med. Uni.-Klinik Graz, Graz, Austria
🇩🇰
Lungemedicinsk Forskning 2B, Aarhus, Denmark
🇩🇰
Bispebjerg Hospital, Copenhagen NV, Denmark

and more 35 locations

A Study to Compare Meloxicam IM Once Daily and Meloxicam Administered Orally Once Daily in Patients With Osteoarthritis

Phase 3

Completed

Conditions: Osteoarthritis

First Posted Date: 2005-10-17

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 168

Registration Number: NCT00239395

Locations: 🇨🇳
People's Hospital, Beijing University, Beijing, China
🇨🇳
Shanghai Guanghai Hospital, Shanghai, China
🇨🇳
Beijing Xuan Wu Hospital, Beijing, China

and more 5 locations

SMOOTH - Blood Pressure Control in Diabetic/Obese Patients

Phase 4

Completed

Conditions: Hypertension
Diabetes Mellitus, Type 2

First Posted Date: 2005-10-17

Last Posted Date: 2013-11-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 840

Registration Number: NCT00239538

Locations: 🇺🇸
1200, Los Angeles, California, United States
🇺🇸
Attention: Larry I. Gilderman, D.O., Pembroke Pines, Florida, United States
🇺🇸
200, Baltimore, Maryland, United States

and more 30 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy